Published in Neoplasia on November 01, 1999
Continued colonization of the human genome by mitochondrial DNA. PLoS Biol (2004) 1.93
Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am J Pathol (2003) 1.61
Thrombospondin-based antiangiogenic therapy. Microvasc Res (2007) 1.26
New molecular targets in angiogenic vessels of glioblastoma tumours. Expert Rev Mol Med (2008) 1.08
Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta. Am J Pathol (2004) 1.02
Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments. Curr Drug Targets (2008) 0.97
Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy. Neuro Oncol (2005) 0.94
Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. Oncogene (2010) 0.89
Protected Graft Copolymer (PGC) in Imaging and Therapy: A Platform for the Delivery of Covalently and Non-Covalently Bound Drugs. Theranostics (2012) 0.88
Enhancing navigation in biomedical databases by community voting and database-driven text classification. BMC Bioinformatics (2009) 0.87
Proteolytically Derived Endogenous Angioinhibitors Originating from the Extracellular Matrix. Pharmaceuticals (Basel) (2011) 0.84
Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action. Pharmaceuticals (Basel) (2010) 0.78
Aiding and ABT'ing Treatment for Glioblastoma. Cancer Biol Ther (2007) 0.77
Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med (1995) 26.60
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 13.94
Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst (1992) 8.69
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 7.66
Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (1994) 5.54
A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A (1990) 5.26
Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (1999) 4.91
Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med (1996) 3.64
Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol (1993) 3.15
Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol (1990) 2.69
Thrombospondin modulates focal adhesions in endothelial cells. J Cell Biol (1989) 2.58
Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res (1994) 2.20
NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med (1998) 2.08
Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci U S A (1996) 2.07
Angiogenesis and angiogenesis inhibition: an overview. EXS (1997) 1.94
Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res (1997) 1.81
Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res (1995) 1.76
Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J (1996) 1.73
Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res (1996) 1.64
Improving MR quantification of regional blood volume with intravascular T1 contrast agents: accuracy, precision, and water exchange. Magn Reson Med (1996) 1.48
Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer (1988) 1.44
Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci U S A (1998) 1.37
Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin. J Cell Biochem (1993) 1.37
Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol (1999) 1.37
Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis. Proc Natl Acad Sci U S A (1995) 1.33
A new macromolecule as a contrast agent for MR angiography: preparation, properties, and animal studies. Radiology (1993) 1.32
Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res (1999) 1.28
The role of thrombospondin-1 in tumor progression and angiogenesis. Bioessays (1996) 1.27
INTRATUMORAL VASCULAR CHANGES WITH INCREASED SIZE OF A MAMMARY ADENOCARCINOMA: NEW METHOD AND RESULTS. J Natl Cancer Inst (1965) 1.26
Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res (1996) 1.23
Expression of thrombospondin-1 in cancer: a role in tumor progression. Proc Soc Exp Biol Med (1996) 1.12
Targeting gene therapy to cancer: a review. Oncol Res (1997) 1.08
Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1. J Pept Res (1997) 1.07
Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res (1998) 1.04
Novel gliosarcoma cell line expressing green fluorescent protein: A model for quantitative assessment of angiogenesis. Microvasc Res (1998) 1.03
Angiostatin suppresses malignant glioma growth in vivo. Cancer Res (1998) 1.02
Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg (1998) 0.99
Non-invasive in vivo mapping of tumour vascular and interstitial volume fractions. Eur J Cancer (1998) 0.98
Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies. Cancer Res (1992) 0.95
Basic physics of MR contrast agents and maximization of image contrast. J Magn Reson Imaging (1993) 0.94
A long-circulating co-polymer in "passive targeting" to solid tumors. J Drug Target (1997) 0.88
Tumor vasculature targeted therapies: getting the players organized. Biochem Pharmacol (1998) 0.82
Vascular volume in B16 allografts and human melanoma xenografts estimated by means of Hoechst 33342. J Pathol (1989) 0.81
Epigenetic memory in induced pluripotent stem cells. Nature (2010) 14.31
A clearer vision for in vivo imaging. Nat Biotechnol (2001) 10.49
Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol (2000) 6.90
Myristyl amino-terminal acylation of murine retrovirus proteins: an unusual post-translational proteins modification. Proc Natl Acad Sci U S A (1983) 5.12
High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem (1999) 4.41
In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med (2001) 4.30
Many pulmonary pathogenic bacteria bind specifically to the carbohydrate sequence GalNAc beta 1-4Gal found in some glycolipids. Proc Natl Acad Sci U S A (1988) 3.83
Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development. Nature (1989) 3.75
Thrombospondin binds falciparum malaria parasitized erythrocytes and may mediate cytoadherence. Nature (1985) 3.53
A potent synthetic peptide inhibitor of the cAMP-dependent protein kinase. J Biol Chem (1986) 3.49
Experimental three-dimensional fluorescence reconstruction of diffuse media by use of a normalized Born approximation. Opt Lett (2001) 3.43
Monocrystalline iron oxide nanocompounds (MION): physicochemical properties. Magn Reson Med (1993) 3.01
Dynamic functional imaging of relative cerebral blood volume during rat forepaw stimulation. Magn Reson Med (1998) 2.98
Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem (1992) 2.93
Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem (1989) 2.87
Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol (1997) 2.52
Pseudomonas aeruginosa and Pseudomonas cepacia isolated from cystic fibrosis patients bind specifically to gangliotetraosylceramide (asialo GM1) and gangliotriaosylceramide (asialo GM2). Arch Biochem Biophys (1988) 2.49
Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J Biol Chem (1995) 2.28
Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology (2001) 2.24
Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res (1994) 2.20
Reactivity of small thiolate anions and cysteine-25 in papain toward methyl methanethiosulfonate. Biochemistry (1986) 2.20
Molecular imaging: exploring the next frontier. Radiology (1999) 2.19
In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res (2000) 2.12
Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation (1999) 2.11
Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology (2000) 2.11
Near-infrared optical imaging of protease activity for tumor detection. Radiology (1999) 1.97
Magnetically labeled cells can be detected by MR imaging. J Magn Reson Imaging (1997) 1.97
The platelet glycoprotein thrombospondin binds specifically to sulfated glycolipids. J Biol Chem (1985) 1.90
Primary structural determinants essential for potent inhibition of cAMP-dependent protein kinase by inhibitory peptides corresponding to the active portion of the heat-stable inhibitor protein. J Biol Chem (1989) 1.89
Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res (1997) 1.81
Platelet thrombospondin mediates attachment and spreading of human melanoma cells. J Cell Biol (1987) 1.81
The activation of human type IV collagenase proenzyme. Sequence identification of the major conversion product following organomercurial activation. J Biol Chem (1989) 1.80
Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J Magn Reson Imaging (1998) 1.77
Adhesion of Mycoplasma pneumoniae to sulfated glycolipids and inhibition by dextran sulfate. J Biol Chem (1989) 1.76
Improvement of MRI probes to allow efficient detection of gene expression. Bioconjug Chem (2000) 1.70
Pulmonary vein dilation in patients with atrial fibrillation: detection by magnetic resonance imaging. J Cardiovasc Electrophysiol (2001) 1.68
Fluorescence molecular imaging of small animal tumor models. Curr Mol Med (2004) 1.62
Paramagnetic metal scavenging by melanin: MR imaging. Radiology (1997) 1.60
Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer (1994) 1.57
Preparation of a cathepsin D sensitive near-infrared fluorescence probe for imaging. Bioconjug Chem (1999) 1.56
Thrombospondin-induced tumor cell migration: haptotaxis and chemotaxis are mediated by different molecular domains. J Cell Biol (1987) 1.56
Activation of the hypothalamus characterizes the acupuncture stimulation at the analgesic point in human: a positron emission tomography study. Neurosci Lett (2001) 1.54
Phosphorylation of Avena phytochrome in vitro as a probe of light-induced conformational changes. J Biol Chem (1986) 1.53
Tunneled peritoneal catheter placement under sonographic and fluoroscopic guidance in the palliative treatment of malignant ascites. AJR Am J Roentgenol (2001) 1.53
The purification and characterization of an extremely thermostable alpha-amylase from the hyperthermophilic archaebacterium Pyrococcus furiosus. J Biol Chem (1993) 1.52
Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles. J Immunol Methods (2001) 1.51
MR imaging of gene delivery to the central nervous system with an artificial vector. Radiology (1998) 1.49
Human transferrin receptor gene as a marker gene for MR imaging. Radiology (2001) 1.48
cDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterases. J Biol Chem (1994) 1.46
Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology (1988) 1.46
Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J Magn Reson Imaging (1999) 1.42
Cell contact-dependent activation of alpha3beta1 integrin modulates endothelial cell responses to thrombospondin-1. Mol Biol Cell (2000) 1.41
Uptake and metabolism of a dual fluorochrome Tat-nanoparticle in HeLa cells. Bioconjug Chem (2003) 1.39
Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin. J Cell Biochem (1993) 1.37
Mouse models of human non-small-cell lung cancer: raising the bar. Cold Spring Harb Symp Quant Biol (2005) 1.37
In vivo imaging of gene expression:. Acad Radiol (2001) 1.36
Validation of diffusion tensor magnetic resonance axonal fiber imaging with registered manganese-enhanced optic tracts. Neuroimage (2001) 1.34
Noninvasive in vivo measurement of beta-cell mass in mouse model of diabetes. Diabetes (2001) 1.34
A new macromolecule as a contrast agent for MR angiography: preparation, properties, and animal studies. Radiology (1993) 1.32
Measuring transferrin receptor gene expression by NMR imaging. Biochim Biophys Acta (1998) 1.31
Pro-adhesive and chemotactic activities of thrombospondin-1 for breast carcinoma cells are mediated by alpha3beta1 integrin and regulated by insulin-like growth factor-1 and CD98. J Biol Chem (1999) 1.29
Molecular imaging of gene therapy for cancer. Gene Ther (2004) 1.28
Analysis of gag proteins from mouse mammary tumor virus. J Virol (1989) 1.27
Heparin-binding peptides from the type I repeats of thrombospondin. Structural requirements for heparin binding and promotion of melanoma cell adhesion and chemotaxis. J Biol Chem (1992) 1.27
Lymphedema: evaluation of qualitative and quantitative lymphoscintigraphy in 238 patients. Radiology (1988) 1.25
Macrocyclic chelators with paramagnetic cations are internalized into mammalian cells via a HIV-tat derived membrane translocation peptide. Bioconjug Chem (2000) 1.25
Laminin binds specifically to sulfated glycolipids. Proc Natl Acad Sci U S A (1985) 1.25
Thrombospondin-1: a physiological regulator of nitric oxide signaling. Cell Mol Life Sci (2008) 1.23
Binding of elastin to Staphylococcus aureus. J Biol Chem (1991) 1.21
Molecular characteristics and functional diversity of CLCA family members. Clin Exp Pharmacol Physiol (2000) 1.21
An active twenty-amino-acid-residue peptide derived from the inhibitor protein of the cyclic AMP-dependent protein kinase. Biochem J (1985) 1.21
MR imaging of phagocytosis in experimental gliomas. Radiology (1995) 1.20
Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin promote melanoma cell adhesion. Proc Natl Acad Sci U S A (1992) 1.20
The development of in vivo imaging systems to study gene expression. Trends Biotechnol (1998) 1.19
Intracellular magnetic labeling of lymphocytes for in vivo trafficking studies. Biotechniques (1998) 1.18
Differential and common recognition of the catalytic sites of the cGMP-dependent and cAMP-dependent protein kinases by inhibitory peptides derived from the heat-stable inhibitor protein. J Biol Chem (1986) 1.16
Identification of an alpha(3)beta(1) integrin recognition sequence in thrombospondin-1. J Biol Chem (1999) 1.13
The breast cancer beta 4 integrin and endothelial human CLCA2 mediate lung metastasis. J Biol Chem (2001) 1.10
Imaging of mediastinal lymph nodes: CT, MR, and FDG PET. Radiographics (1998) 1.10
Trapping of dextran-coated colloids in liposomes by transient binding to aminophospholipid: preparation of ferrosomes. Biochim Biophys Acta (1994) 1.10
Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. Eur J Cancer (2000) 1.10
Cloning and characterization of lung-endothelial cell adhesion molecule-1 suggest it is an endothelial chloride channel. J Biol Chem (1997) 1.08
Salicylamide derivatives related to medroxalol with alpha- and beta-adrenergic antagonist and antihypertension activity. J Med Chem (1981) 1.08
Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1. J Pept Res (1997) 1.07
Biosynthesis of the 67 kDa high affinity laminin receptor. Biochem Biophys Res Commun (1991) 1.07
Cardiovascular properties of medroxalol, a new antihypertensive drug. J Cardiovasc Pharmacol (1981) 1.06
The collagen binding domain of fibronectin contains a high affinity binding site for Candida albicans. J Biol Chem (1994) 1.05